Allergic Conjunctivitis Management: Update on Ophthalmic Solutions.

IF 5.4 2区医学 Q1 ALLERGY Current Allergy and Asthma Reports Pub Date : 2024-07-01 Epub Date: 2024-06-13 DOI:10.1007/s11882-024-01150-0

Andrea Leonardi, Luigi Quintieri, Ignacio Jáuregui Presa, Jesús Merayo LLoves, Jesús Montero, José Manuel Benítez-Del-Castillo, Francisco Javier Seoane Lestón, Eloína González-Mancebo, Riccardo Asero, Anna Groblewska, Piotr Kuna

{"title":"Allergic Conjunctivitis Management: Update on Ophthalmic Solutions.","authors":"Andrea Leonardi, Luigi Quintieri, Ignacio Jáuregui Presa, Jesús Merayo LLoves, Jesús Montero, José Manuel Benítez-Del-Castillo, Francisco Javier Seoane Lestón, Eloína González-Mancebo, Riccardo Asero, Anna Groblewska, Piotr Kuna","doi":"10.1007/s11882-024-01150-0","DOIUrl":null,"url":null,"abstract":"Purpose of review: The aim of this review, is to present an updated revision of topical management of SAC and PAC, based on the available scientific evidence and focused on the impact of ophthalmic solution formulations on eye surface.Recent findings: Physicians treating ocular allergy should be aware of tear film and tear film disruption in SAC and PAC, and how eye drop composition and additives affect the physiology of the allergic eye. Seasonal and perennial allergic conjunctivitis (SAC and PAC) are the most frequent causes of ocular allergy (OA), and both conditions are underdiagnosed and undertreated. SAC and PAC are immunoglobulin E (IgE)-mediated hypersensitivity reactions. The additional tear film disruption caused by the release of inflammatory mediators increases and exacerbates the impact of signs and symptoms and may trigger damage of the ocular surface. Comorbidities are frequent, and dry eye disease in particular must be considered. Clinical guidelines for the management of SAC and PAC recommend topical therapy with antihistamines, mast cells stabilizers or dualaction agents as first-line treatment, but care should be taken, as many medications contain other compounds that may contribute to ocular surface damage.","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"347-360"},"PeriodicalIF":5.4000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233348/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Allergy and Asthma Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11882-024-01150-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The aim of this review, is to present an updated revision of topical management of SAC and PAC, based on the available scientific evidence and focused on the impact of ophthalmic solution formulations on eye surface.

Recent findings: Physicians treating ocular allergy should be aware of tear film and tear film disruption in SAC and PAC, and how eye drop composition and additives affect the physiology of the allergic eye. Seasonal and perennial allergic conjunctivitis (SAC and PAC) are the most frequent causes of ocular allergy (OA), and both conditions are underdiagnosed and undertreated. SAC and PAC are immunoglobulin E (IgE)-mediated hypersensitivity reactions. The additional tear film disruption caused by the release of inflammatory mediators increases and exacerbates the impact of signs and symptoms and may trigger damage of the ocular surface. Comorbidities are frequent, and dry eye disease in particular must be considered. Clinical guidelines for the management of SAC and PAC recommend topical therapy with antihistamines, mast cells stabilizers or dualaction agents as first-line treatment, but care should be taken, as many medications contain other compounds that may contribute to ocular surface damage.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

过敏性结膜炎管理：最新眼科解决方案。

综述目的：本综述旨在根据现有的科学证据，对 SAC 和 PAC 的局部治疗方法进行最新修订，重点关注眼科溶液配方对眼表的影响：治疗眼部过敏的医生应了解 SAC 和 PAC 的泪膜和泪膜破坏，以及眼药水成分和添加剂如何影响过敏眼的生理机能。季节性和常年性过敏性结膜炎（SAC 和 PAC）是眼部过敏（OA）最常见的病因，这两种疾病诊断不足、治疗不彻底。SAC 和 PAC 是免疫球蛋白 E（IgE）介导的超敏反应。炎症介质的释放造成的额外泪膜破坏会增加和加剧症状和体征的影响，并可能引发眼表损伤。合并症很常见，尤其必须考虑干眼症。治疗 SAC 和 PAC 的临床指南建议使用抗组胺剂、肥大细胞稳定剂或双效制剂进行局部治疗，作为一线治疗方法，但应注意的是，许多药物都含有可能导致眼表损伤的其他化合物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Allergy and Asthma Reports 医学-过敏

CiteScore

11.20

自引率

1.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of Current Allergy and Asthma Reports is to systematically provide the views of highly selected experts on current advances in the fields of allergy and asthma and highlight the most important papers recently published. All reviews are intended to facilitate the understanding of new advances in science for better diagnosis, treatment, and prevention of allergy and asthma. We accomplish this aim by appointing international experts in major subject areas across the discipline to review select topics emphasizing recent developments and highlighting important new papers and emerging concepts. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Over a one- to two-year period, readers are updated on all the major advances in allergy and asthma.

期刊最新文献

Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta-analysis. Hypersensitivity Reactions to Anticonvulsants. The Impact of the Indoor Environment on Childhood Asthma. Parosmia: Pathophysiology and Management. Effects of Food Processing on Allergenicity.